GLP-1类似物—度拉鲁肽研究进展

Research progress in GLP-1 analogue durarupeptide

度拉糖肽是美国礼来公司研发的新型长效GLP-类似物,已在美国上市,2017年美国糖尿病治疗指南建议在口服单药治疗不佳时可以联合使用GLP-1受体激动剂降糖,其独特的分子结构使其免疫原性最小化,具有超长的半衰期,每周一次的用药方式大大提高了患者的依从性,并多项实验研究表明,度拉糖肽可与多种降糖药物联合使用,能有效降糖及糖化血红蛋白,减轻患者体重,保护胰岛B细胞,极少发生低血糖,恶心、腹胀等不良反应少,且多为一过性,临床应用安全有效,是值得推广的一类降糖新药。

Durarupeptide is a new long-acting GLP-analogue developed by Eli Lilly and Company,which has been listed in the US.The 2017 American Diabetes Treatment Guidelines recommend a combination of GLP-1 receptor agonist hypoglycemic in the case of poor oral monotherapy and its unique molecular structure minimizes its immunogenicity.It has an extremely long half-life,and the weekly regimen significantly improves patient compliance.A number of experimental studies have shown that durarupeptide can be used in combination with a variety of hypoglycemic drugs,which can effectively lower blood glucose and glycosylated hemoglobin,reduce the weight of patients and protect islet B cells.Hypoglycemia,nausea,abdominal distension and other adverse reactions are rare and mostly transient.The clinical application is safe and effective,and it is a new type of hypoglycemic drug worth promoting.